Trial Profile
Phase II study of vinflunine and cetuximab in the second line treatment of stage IIIB/IV non-small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Jun 2017
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Vinflunine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Jan 2012 Actual patient number is 16 according to ClinicalTrials.gov.
- 20 Jan 2012 Actual patient number is 16 according to ClinicalTrials.gov.
- 20 Jan 2012 Planned end date 1 Nov 2009 added as reported by ClinicalTrials.gov..